camizestrant
Selected indexed studies
- First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. (N Engl J Med, 2025) [PMID:40454637]
- Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. (Future Oncol, 2023) [PMID:37070653]
- Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial. (Lancet Oncol, 2024) [PMID:39481395]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. (2025) pubmed
- Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. (2023) pubmed
- Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial. (2024) pubmed
- The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance. (2023) pubmed
- Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1. (2025) pubmed
- CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer. (2025) pubmed
- A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results. (2024) pubmed
- Camizestrant causes reversible pharmacological effects on retinal responses in rats. (2025) pubmed
- Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer. (2024) pubmed
- New Oral Selective Estrogen Receptor Degraders Redefine Management of Estrogen Receptor-Positive Breast Cancer. (2025) pubmed